ArticleJournal of immunology (Baltimore, Md. : 1950)2012
New biomarkers with relevance to leprosy diagnosis applicable in areas hyperendemic for leprosy.
Article in Journal of immunology (Baltimore, Md. : 1950), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 85 citations in OpenAlex.
- Longitudinal assessment of anti-PGL-I serology in contacts of leprosy patients in Bangladesh.PLoS neglected tropical diseases · 2017Trial
- Safety and efficacy assessment of two new leprosy skin test antigens: randomized double blind clinical study.PLoS neglected tropical diseases · 2014Trial
- The combined effect of chemoprophylaxis with single dose rifampicin and immunoprophylaxis with BCG to prevent leprosy in contacts of newly diagnosed leprosy cases: a cluster randomized controlled trial (MALTALEP study).BMC infectious diseases · 2013Trial
- Leprosy.Nature reviews. Disease primers · 2024Review
- The Neurological Impact of Leprosy: Manifestations and Treatment Approaches.Neurology international · 2024Review
- Sequential trypsin and ProAlanase digestions unearth immunological protein biomarkers shrouded by skeletal collagen.iScience · 2024Article
- The landscape of chemokine and cytokine is associated with the distinct clinical status of leprosy patients and their respective household contacts.Frontiers in immunology · 2024Article
- Interplay among differential exposure toFrontiers in immunology · 2023Article
- Altered cytokine profiles in relapsed paucibacillary leprosy: a case report.BMC infectious diseases · 2021Article
- Autophagy-Associated IL-15 Production Is Involved in the Pathogenesis of Leprosy Type 1 Reaction.Cells · 2021Article
- In search of biomarkers for leprosy by unraveling the host immune response to Mycobacterium leprae.Immunological reviews · 2021Review
- Susceptibility and resistance in leprosy: Studies in the mouse model.Immunological reviews · 2021Review
- Insights intoProteomes · 2021Review
- Potential Role of CXCL10 in Monitoring Response to Treatment in Leprosy Patients.Frontiers in immunology · 2021Article
- Transcriptomic Analysis ofFrontiers in cellular and infection microbiology · 2021Article
- Functional biomarker signatures of circulating T-cells and its association with distinct clinical status of leprosy patients and their respective household contacts.Infectious diseases of poverty · 2020Article
- Application of new host biomarker profiles in quantitative point-of-care tests facilitates leprosy diagnosis in the field.EBioMedicine · 2019Article
- Host immune responses induced by specific Mycobacterium leprae antigens in an overnight whole-blood assay correlate with the diagnosis of paucibacillary leprosy patients in China.PLoS neglected tropical diseases · 2019Article
- CR3 Engaged by PGL-I Triggers Syk-Calcineurin-NFATc to Rewire the Innate Immune Response in Leprosy.Frontiers in immunology · 2019Article
- Evaluation of Immunodiagnostic Tests for Leprosy in Brazil, China and Ethiopia.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 8 institutions in 7 countries.
Funding
Abstract
Leprosy is not eradicable with currently available diagnostics or interventions, as evidenced by its stable incidence. Early diagnosis of Mycobacterium leprae infection should therefore be emphasized in leprosy research. It remains challenging to develop tests based on immunological biomarkers that distinguish individuals controlling bacterial replication from those developing disease. To identify biomarkers for field-applicable diagnostics, we determined cytokines/chemokines induced by M. leprae proteins in blood of leprosy patients and endemic controls (EC) from high leprosy-prevalence areas (Bangladesh, Brazil, Ethiopia) and from South Korea, where leprosy is not endemic anymore. M. leprae-sonicate-induced IFN-γ was similar for all groups, excluding M. leprae/IFN-γ as a diagnostic readout. By contrast, ML2478 and ML0840 induced high IFN-γ concentrations in Bangladeshi EC, which were completely absent for South Korean controls. Importantly, ML2478/IFN-γ could indicate distinct degrees of M. leprae exposure, and thereby the risk of infection and transmission, in different parts of Brazilian and Ethiopian cities. Notwithstanding these discriminatory responses, M. leprae proteins did not distinguish patients from EC in one leprosy-endemic area based on IFN-γ. Analyses of additional cytokines/chemokines showed that M. leprae and ML2478 induced significantly higher concentrations of MCP-1, MIP-1β, and IL-1β in patients compared with EC, whereas IFN-inducible protein-10, like IFN-γ, differed between EC from areas with dissimilar leprosy prevalence. This study identifies M. leprae-unique Ags, particularly ML2478, as biomarker tools to measure M. leprae exposure using IFN-γ or IFN-inducible protein-10, and also shows that MCP-1, MIP-1β, and IL-1β can potentially distinguish pathogenic immune responses from those induced during asymptomatic exposure to M. leprae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.